A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

@inproceedings{Mross2012ARP,
  title={A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-na{\"i}ve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network},
  author={K. Mross and Christian Dittrich and Walter Erich Aulitzky and Dirk Strumberg and J. J. W. Schutte and Roland M Schmid and Stephan Hollerbach and Michael Merger and Gerd Munzert and F. Fleischer and Max Ernst Scheulen},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas.Methods:The study employed a two-stage design. Randomised first-line patients received BI 2536 200 mg on day 1 (n=43) or 60 mg on days 1–3 (n=43) every 21 days. Recruitment of second-line patients was planned for a second stage dependent on an interim analysis demonstrating ⩾2 responses in the first 18 evaluable patients following 12 weeks of… CONTINUE READING